1. Home
  2. Vol 53, No 2 (2021)
  3. Soedarsono

The Risk Factors of Multidrug-Resistant Organisms in Hospitalized Patients with Community-Acquired Pneumonia in Dr. Soetomo Hospital Surabaya, Indonesia

Soedarsono Soedarsono, Putu Dyah Widyaningsih, Ni Made Mertaniasih

Abstract


Background: multidrug-resistant organisms (MDRO) caused pneumonia has become a crucial case. MDRO infection has been a problem concern to community-acquired pneumonia (CAP). A lot of factors play roles in CAP with MDRO infection. This study aimed to analyze MDRO as the etiology of hospitalized patients with CAP along with its risk factors in Dr. Soetomo Hospital as one of the top referral hospitals in east Indonesia. Methods: this retrospective cohort study was conducted from January 2016 to December 2018. Data were collected from patients’ medical records. Automatic Rapid Diagnosis (Phoenix TM) was used as a standard method for culture and susceptibility test. Various risk factors were analyzed for MDRO infection. Results: five most common pathogens in hospitalized patients with CAP were Acinetobacter baumannii 244/1364 (17.9%), Klebsiella pneumoniae 134/1364 (9.8%), Pseudomonas aeruginosa 91/1364 (6.7%), Escherichia coli 58/1364 (4.3%), and Enterobacter cloacae 45/1364 (3.3%). There were 294/1364 (21.5%) MDROs isolated from patients with CAP. MDRO infection was linked to previous hospitalization, malignancy, cardiovascular disease, and structural lung disease with p values of 0.002, <0.001, 0.024, and <0.001, respectively. Conclusion: the incidence of MDRO in CAP is high (21.5%). The risk factors related were previous hospitalization, malignancy, cardiovascular disease, and structural lung disease.

Keywords


Risk Factors; Multidrug-Resistant Organisms; Community-Acquired Pneumonia

References


New Hampshire Department of Health and Human Services (NH DHHS). Recommendations for the prevention and control of multidrug-resistant organisms (MDROs) and Clostridium difficile infection (CDI) for healthcare agencies and community settings. The State of New Hampshire: NH DHHS; 2015. p. 12.

Kanoksil M, Jatapai A, Peacock SJ, Limmathurotsakul D. Epidemiology, microbiology and mortality associated with community-acquired bacteremia in Northeast Thailand: a multicenter surveillance study. PLoS ONE. 2013;8:e54714.

Ansari S, Nepal HP, Gautam R, et al. Community acquired multidrug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal. Antimicrob Resist Infect Control. 2015;4:1-8.

Wilson SJ, Knipe CJ, Zieger MJ, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control. 2004;32:342–4.

Qavi A, Segal-Maurer S, Mariano N, et al. Increased mortality associated with a clonal outbreak of ceftazidime-resistant Klebsiella pneumoniae: a case-control study. Infect Control Hosp Epidemiol. 2005;26:63–8.

Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin resistant Enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol. 2003;24:251–6.

American Thoracic Society; Infectious Diseases Society of America (ATS IDSA). Guidelines for the management of adults with hospital acquired, ventilatory-associated, and healthcare- associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.

American Thoracic Society; Infectious Diseases Society of America (ATS IDSA). Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63:61-111.

Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-82.

Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an International expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.

Vinogradova Y, Julia H, Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract. 2009;59:e329-38.

Cukic V, Hadzic A. The most common detected bacteria in sputum of patients with community acquired pneumonia (cap) treated in hospital. Med Arch. 2016;70:354-8.

Acharya VK, Padyana M, Unnikrishnan B, Anand R, Acharya PR, Juneja DJ. Microbiological profile and drug sensitivity pattern among community acquired pneumonia patients in tertiary care centre in Mangalore, Coastal Karnataka, India. J Clinical Diagnostic Research. 2014;8:4-16.

Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother. 2014;58:5262-8.

Di Pasquale M, Aliberti S, Sotgiu G, Gramegna A, Terrano S. A worldwide evaluation of multi-drug resistant organisms in nursing home acquired pneumonia. Am J Respir Crit Care Med. 2017;195:A6860.

Cilloniz C, Gabarruz A, Ferrer M, et al. Community-acquired pneumonia due to multidrug- and non-multidrug-resistant Pseudomonas aeruginosa. Chest. 2016;150:415-25.

Rice L. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197:1079-81.

Sievert DM, Ricks P, Jonathan R, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34:1-14.

Mwanri L, Essa A. Multi-drug resistant organisms and patients’ risk factors in the intensive care unit of King Fahad Hofuf Hospital, Saudi Arabia. Int J Health Psychology Research. 2014;2:8-25.

Exner M, Bhattacharya S, Christiansen B, et al. Antibiotic resistance: what is so special about multidrug-resistant Gram-Negative bacteria?. GMB Hyg Infect Control. 2017;12:1-24.

Drinka P, Niederman MS, El-Solh AA, Cmich CJ. Assessment of risk factors for multi-drug resistant organisms to guide empiric antibiotic selection in long term care: a dilemma. J Am Med Dir Assoc. 2011;12:321-5.

Huang H, Chen B, Liu G, et al. A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii. BMC Infect Dis. 2018;18:1-6.

Mody L, Gibson KE, Horcher A, et al. Prevalence of and risk factors for multidrug-resistant Acinetobacter baumannii colonization among high-risk nursing home residents. Infect Control Hosp Epidemiol. 2015;36:1155-62.

Silva N, Oliveira M, Bandeira AC, Brites C. Risk factors for infection by extended-spectrum beta-lactamase producing Klebsiella pneumoniae in a tertiary hospital in Salvador, Brazil. Braz J Infect Dis. 2006;10:191-3.

Cheng WL, Hsueh PR, Lee CC, et al. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: appropriateness of empirical treatment matters. J Microbiol Immunol Infect. 2016;49:208-15.

Dantas RC, Ferreira ML, Fiho PP, Ribas RM. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. J Med Microbiol. 2014;63:1679-87.

Jeong BH, Koh WJ, Yoo H, et al. Risk factors for acquiring potentially drug-resistant pathogens in immunocompetent patients with pneumonia developed out of hospital. Respiration. 2014;88:190-8.

Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrug resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis. 2012;54:470-8.

Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. J Infect Control. 2007;35:65-164.


Full Text: PDF

Refbacks

  • There are currently no refbacks.